ANSWER: C

Rationale:

The correct answer is C. The standard protocol for sublingual nitroglycerin in acute angina is one tablet (0.4 mg) under the tongue at symptom onset with the patient seated or supine. SL-NTG has an onset of 1–3 minutes and peak effect at approximately 5 minutes — the 5-minute repeat interval is precisely calibrated to this pharmacokinetic profile. If no relief after 5 minutes, a second tablet is taken; if still no relief after another 5 minutes, a third. If chest pain is not relieved after three doses over approximately 15 minutes, emergency services must be activated immediately. Persistent pain unresponsive to three doses of nitroglycerin must be treated as a possible acute coronary syndrome requiring urgent evaluation.

• Option A: Option A is incorrect: a 30-minute wait before repeating and a 60-minute window before calling 911 are dangerously prolonged — an evolving myocardial infarction causes irreversible myocardial damage within this time frame.
• Option B: Option B is incorrect: SL-NTG must dissolve under the tongue and be absorbed through the sublingual mucosa directly into the systemic circulation; swallowing the tablet causes nearly complete first-pass hepatic metabolism, eliminating its pharmacological effect.
• Option D: Option D is incorrect: doubling the initial dose increases orthostatic hypotension risk without improving efficacy; standard dosing is one tablet at a time.
• Option E: Option E is incorrect: repeating every 10 minutes for up to five doses and waiting for loss of consciousness or severe hypotension before calling emergency services delays potentially life-saving ACS care by an unacceptable interval. ---

ANSWER: A

Rationale:

The correct answer is A. Nitroglycerin produces venodilation that pools blood in the peripheral venous system, reducing venous return and lowering blood pressure. In a standing patient — particularly one who is elderly, hypovolemic, or taking other vasodilators or alcohol — this blood pressure reduction can cause orthostatic hypotension and syncope, with risk of falls and injury. The risk is greatest with the first dose of a new nitrate formulation, before the patient is familiar with the drug's hemodynamic effect. Instructing M.R. to sit or lie down before use is a simple and critical safety measure that prevents syncope-related falls. She should remain seated until symptoms resolve and she feels hemodynamically stable.

• Option B: Option B is incorrect: body position does not meaningfully alter sublingual absorption; the sublingual mucosa is highly vascular regardless of posture, and the 1–3 minute onset is pharmacokinetically determined by mucosal blood flow and drug diffusion, not by body position-related blood pooling.
• Option C: Option C is incorrect: the hemodynamic effect of SL-NTG is clinically significant — a reduction of 10–20 mmHg in systolic blood pressure is common after the first dose, which is sufficient to cause orthostatic hypotension in susceptible patients.
• Option D: Option D is incorrect: while the seated position does have modest effects on baroreceptor sensitivity, this is not the reason for the instruction; the primary safety concern is preventing syncope and falls from orthostatic hypotension, not blunting reflex tachycardia.
• Option E: Option E is incorrect: the hydrostatic equalization benefit of the supine position on coronary perfusion is physiologically real but clinically minor compared to the pharmacological mechanism; the reason for the instruction is hemodynamic safety, not coronary perfusion optimization. CASE 2 P.K. is a 58-year-old man with stable angina who has been prescribed isosorbide mononitrate immediate-release (ISMN-IR) 20 mg twice daily for chronic prophylaxis. His pharmacy fills the prescription with the label reading "Take one tablet twice daily." He calls the clinic to ask what time he should take his doses. ---

ANSWER: D

Rationale:

The correct answer is D. ISMN-IR has a duration of action of approximately 6–8 hours. The correct eccentric dosing schedule is the first dose at 7:00 AM and the second at 2:00 PM. With this schedule, the second dose's pharmacological effect wanes by approximately 8:00–10:00 PM, providing a nitrate-free interval of approximately 10–12 hours through the evening and overnight. During this interval, oxidatively inactivated mitochondrial aldehyde dehydrogenase 2 (ALDH2) is regenerated, neurohormonal pseudotolerance resolves, and vascular nitrate sensitivity is restored — ensuring that the 7:00 AM dose the following morning retains full efficacy.

• Option A: Option A is incorrect: 8:00 AM and 8:00 PM appears symmetrical and logical but is precisely wrong — the second dose at 8:00 PM extends drug effect through approximately 2:00–4:00 AM, virtually eliminating the overnight nitrate-free interval and causing tolerance within 24–48 hours.
• Option B: Option B is incorrect: noon and midnight dosing fails to provide anti-ischemic coverage during the morning hours of peak angina risk (6:00–10:00 AM), when sympathetic tone, platelet aggregability, and coronary vasomotor reactivity peak; this schedule is clinically inappropriate.
• Option C: Option C is incorrect: 7:00 AM and 11:00 PM creates near-continuous nitrate exposure — the 11:00 PM dose extends drug effect through approximately 5:00–7:00 AM, eliminating the nitrate-free interval and guaranteeing tolerance.
• Option E: Option E is incorrect: 6:00 AM and 6:00 PM is the same structural error as Option A — a symmetrical evening dose eliminates the overnight nitrate-free interval. ISMN-IR does not require food for tolerability and gastrointestinal side effects are not the primary scheduling consideration. ---

ANSWER: B

Rationale:

The correct answer is B. The 7:00 AM and 7:00 PM schedule is the most common prescribing error with ISMN-IR and is precisely the schedule that eliminates the nitrate-free interval. ISMN-IR has a duration of action of approximately 6–8 hours; a dose taken at 7:00 PM extends pharmacological effect through approximately 1:00–3:00 AM. The overnight hours therefore contain continuous nitrate exposure rather than the required nitrate-free interval. Without this interval, mitochondrial aldehyde dehydrogenase 2 (ALDH2) — progressively inactivated by reactive oxygen species generated during nitroglycerin bioactivation — is never regenerated. Neurohormonal pseudotolerance from renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system (SNS) activation is never resolved. Within 24–48 hours, full tolerance develops and the drug produces minimal hemodynamic effect at the prescribed dose. P.K. should be corrected to the 7:00 AM / 2:00 PM eccentric schedule, which will restore efficacy within days of re-establishing the overnight nitrate-free interval.

• Option A: Option A is incorrect: sGC receptor desensitization is not the primary mechanism of nitrate tolerance, and a two-week washout is not required; restoring the nitrate-free interval via correct eccentric dosing reverses tolerance rapidly.
• Option C: Option C is incorrect: ISMN does not require ALDH2 for bioactivation — it is already the active mononitrate form; pharmacogenomic ALDH2 variants do not explain ISMN tolerance, which is driven by dosing schedule error.
• Option D: Option D is incorrect: the 12-hour dosing interval is not too long — ISMN-IR with a 7-hour gap between 7:00 AM and 2:00 PM doses provides adequate coverage; the problem is the 7:00 PM evening dose, not the dosing interval duration.
• Option E: Option E is incorrect: organic nitrate tolerance does not involve cross-tolerance to endogenous eNOS-derived NO; eNOS function may be impaired by chronic nitrate use through superoxide mechanisms, but re-sensitization does not require antioxidant supplementation as a standard intervention. CASE 3 W.T. is a 71-year-old man with stable angina who was prescribed a transdermal nitroglycerin patch 0.4 mg/hour two weeks ago. He calls his physician reporting that the patch stopped working after the first week. On review, he has been wearing the patch continuously without removing it, interpreting the once-daily patch labeling as meaning he should apply a new patch each morning while leaving the previous one in place overnight. ---

ANSWER: E

Rationale:

The correct answer is E. The primary mechanism of nitrate tolerance is oxidative inactivation of mitochondrial aldehyde dehydrogenase 2 (ALDH2). During nitroglycerin (GTN) bioactivation, ALDH2 catalyzes the conversion of GTN to inorganic nitrite and subsequently nitric oxide (NO), generating reactive oxygen species — superoxide and peroxynitrite — as byproducts. These reactive species accumulate during continuous nitrate exposure and oxidatively damage ALDH2 itself. Without a daily nitrate-free interval (NFI) during which ALDH2 can be regenerated, the enzyme is progressively inactivated and NO production falls, reducing the vasodilatory response. Tolerance develops within 24–48 hours of uninterrupted exposure — explaining why W.T.'s patch was ineffective by the end of the first week. The solution is to apply the patch in the morning and remove it in the evening, providing a 10–12 hour overnight NFI.

• Option A: Option A is incorrect: nitroglycerin does not act through beta-2 adrenoceptors; its mechanism is entirely through NO-sGC-cGMP signaling. Vascular smooth muscle beta-2 adrenoceptor desensitization is not a mechanism of nitrate tolerance.
• Option B: Option B is incorrect: transdermal NTG patches maintain drug stability in the reservoir for the labeled wear period; progressive drug degradation in the patch is not the mechanism of clinical tolerance.
• Option C: Option C is incorrect: skin receptor saturation is not a recognized pharmacological mechanism; transdermal absorption is a physicochemical process driven by concentration gradient, not by receptor-mediated uptake.
• Option D: Option D is incorrect: sGC downregulation is a proposed secondary molecular adaptation in chronic NO exposure but is not the primary established mechanism of clinical nitrate tolerance; ALDH2 inactivation is the primary mechanism. ---

ANSWER: C

Rationale:

The correct answer is C. The correct transdermal nitroglycerin regimen is to apply the patch in the morning (typically 7:00–8:00 AM) and remove it in the evening (typically 7:00–8:00 PM), providing approximately 12 hours of drug delivery followed by a 10–12 hour overnight nitrate-free interval (NFI). During the NFI, mitochondrial aldehyde dehydrogenase 2 (ALDH2) is regenerated, neurohormonal pseudotolerance resolves, and vascular nitrate sensitivity is restored for the following morning's application. Critically, the overnight NFI coincides with the period of highest circadian angina risk — the early morning hours of peak sympathetic tone, platelet aggregability, and coronary vasomotor reactivity. A beta-blocker or non-dihydropyridine CCB (verapamil or diltiazem) must therefore be continued through the NFI to maintain uninterrupted non-nitrate anti-ischemic protection.

• Option A: Option A is incorrect: 24-hour continuous patch wear is exactly the error W.T. made; replacing the patch every 24 hours does not provide a nitrate-free interval and guarantees tolerance regardless of how often the patch is replaced.
• Option B: Option B is incorrect: every-other-day dosing is not a recognized or evidence-based transdermal NTG regimen; it would leave the patient without anti-ischemic protection on patch-free days and is not how the nitrate-free interval is implemented clinically.
• Option D: Option D is incorrect: applying at bedtime and removing in the morning reverses the anti-ischemic coverage window; most exertional angina occurs during waking hours, and the early morning peak-risk period would be covered only by the tail of drug effect as the patch is removed.
• Option E: Option E is incorrect: rotating application sites is recommended to prevent local skin irritation, but it does not prevent systemic tolerance — tolerance from ALDH2 inactivation occurs at the vascular enzymatic level, not at the skin absorption site. CASE 4 R.S. is a 66-year-old man who presents to the emergency department with an acute inferior wall STEMI. His blood pressure is 78/52 mmHg and his heart rate is 94 bpm. Right-sided electrocardiographic leads show ST elevation in V4R. A resident prepares to administer intravenous nitroglycerin for symptom control. ---

ANSWER: A

Rationale:

The correct answer is A. ST elevation in lead V4R (right-sided precordial lead) is the diagnostic finding for right ventricular (RV) infarction, which complicates approximately 30–50% of inferior wall STEMIs due to occlusion of the right coronary artery proximal to the RV marginal branches. The infarcted RV cannot generate normal contractile force and becomes critically dependent on adequate venous return and filling pressure (preload) to maintain output across the pulmonary vasculature and into the left heart. Nitroglycerin's primary hemodynamic action is venodilation with reduction in venous return. In RV infarction, administering NTG removes the preload reserve on which RV output depends: RV output collapses, pulmonary blood flow falls, LV filling is lost, and systemic blood pressure drops precipitously. ST elevation in V4R is therefore the specific finding that triggers this absolute contraindication.

• Option B: Option B is incorrect: IV-NTG is recommended (ACC/AHA Class I) for persistent ischemic symptoms, hypertension, and pulmonary congestion in most STEMI presentations; the contraindication is specifically to RV infarction, not all inferior STEMIs.
• Option C: Option C is incorrect: while SBP below 90 mmHg is a general caution for nitrate use, the specific absolute contraindication here is RV infarction physiology — preload dependence — not merely the blood pressure threshold.
• Option D: Option D is incorrect: reflex tachycardia is a real adverse effect of nitrates that is problematic in ischemia, but it is not the mechanism of the absolute contraindication in RV infarction; the mechanism is preload-dependent RV failure.
• Option E: Option E is incorrect: PDE5 inhibitor use cannot be assumed from demographics or hemodynamic findings and requires direct patient questioning; the contraindication in this case is RV infarction physiology, not a presumed drug interaction. ---

ANSWER: D

Rationale:

The correct answer is D. In right ventricular (RV) infarction, the management of hypotension is the opposite of vasodilation — the RV is preload-dependent and requires increased venous return and filling pressure to generate output. Isotonic saline (0.9% NaCl) volume loading increases venous return to the right heart, restoring RV filling pressure and output, improving pulmonary blood flow, and increasing left ventricular preload — restoring systemic blood pressure. This is the first-line treatment for hypotension in confirmed RV infarction. One or more boluses of 250–500 mL isotonic saline are administered while hemodynamic response is monitored.

• Option A: Option A is incorrect: while dopamine may be used in cardiogenic shock refractory to volume loading, isotonic saline is the correct first-line intervention in RV infarction hypotension; vasopressors are not the initial management step when the primary problem is inadequate preload.
• Option B: Option B is incorrect: norepinephrine increases afterload through alpha-1 vasoconstriction, which may worsen RV function by increasing pulmonary vascular resistance in addition to systemic resistance; volume loading to restore preload is the physiologically correct first step.
• Option C: Option C is incorrect: furosemide reduces preload by promoting venous capacitance and diuresis — the opposite of what is needed in RV infarction, where preload must be maintained and increased. Administering furosemide in RV infarction would worsen hypotension and potentially cause hemodynamic collapse.
• Option E: Option E is incorrect: all nitrate formulations — including sublingual — are absolutely contraindicated in RV infarction regardless of dose or route, because the mechanism of harm (venodilation with preload reduction) applies at any effective nitrate concentration. CASE 5 C.M. is a 55-year-old woman with hypertrophic obstructive cardiomyopathy (HOCM) confirmed on echocardiography. She develops exertional chest pain and is seen by a locum physician unfamiliar with her history. The locum prepares to prescribe sublingual nitroglycerin for her angina. ---

ANSWER: B

Rationale:

The correct answer is B. In hypertrophic obstructive cardiomyopathy (HOCM), dynamic obstruction of the left ventricular outflow tract (LVOT) is caused by systolic anterior motion (SAM) of the anterior mitral leaflet toward the hypertrophied interventricular septum. The severity of this obstruction is directly dependent on left ventricular volume: a smaller LV cavity during systole brings the anterior mitral leaflet geometrically closer to the septum, worsening LVOT obstruction and reducing forward cardiac output. Any intervention that reduces LV filling — nitroglycerin-induced venodilation with reduced venous return, dehydration, the Valsalva maneuver, or standing — decreases LV volume and worsens obstruction, potentially causing syncope or hemodynamic collapse. Organic nitrates are therefore absolutely contraindicated in HOCM. The correct pharmacological management of angina in HOCM is with beta-blockers (reduce heart rate and contractility, decreasing the LVOT gradient) or verapamil (a non-dihydropyridine CCB that reduces heart rate and improves diastolic filling).

• Option A: Option A is incorrect: while reflex tachycardia from nitrates does worsen HOCM (shortened diastolic filling time reduces LV volume and worsens obstruction), this is not the primary mechanism of the absolute contraindication; the preload reduction and consequent LV volume reduction is the primary mechanism.
• Option C: Option C is incorrect: cGMP does not sensitize cardiomyocytes to calcium; cGMP mediates vascular smooth muscle relaxation and does not produce direct myocardial calcium channel effects.
• Option D: Option D is incorrect: nitrates at standard doses produce predominantly venodilation (preload reduction), not arteriolar dilation (afterload reduction). Afterload reduction would theoretically reduce the LVOT gradient by lowering impedance to outflow — it is preload reduction that is specifically harmful in HOCM.
• Option E: Option E is incorrect: coronary steal in the hypertrophied septum is not an established mechanism of nitrate contraindication in HOCM; the contraindication is based on the hemodynamic consequence of LV preload reduction and LV volume reduction. ---

ANSWER: E

Rationale:

The correct answer is E. Beta-blockers are first-line pharmacological therapy for both angina and LVOT obstruction management in hypertrophic obstructive cardiomyopathy (HOCM). Metoprolol succinate (or other beta-1 selective blockers) reduces heart rate, which prolongs diastolic filling time and increases LV end-diastolic volume — increasing LV cavity size and reducing LVOT obstruction. Reduced contractility decreases the velocity of systolic ejection, which reduces the Venturi effect that drives systolic anterior motion (SAM) of the anterior mitral leaflet. Both effects reduce the dynamic LVOT gradient and decrease myocardial oxygen demand, relieving angina. Non-dihydropyridine CCBs — specifically verapamil — are an alternative when beta-blockers are contraindicated.

• Option A: Option A is incorrect: amlodipine is a dihydropyridine CCB with predominant arteriolar vasodilatory activity. Dihydropyridine CCBs are generally avoided in HOCM because their afterload reduction can reflexively increase contractility and heart rate (via baroreceptor activation), and their vasodilatory effect can reduce LV preload — both of which worsen LVOT obstruction. Only non-dihydropyridine CCBs (verapamil) are appropriate in HOCM.
• Option B: Option B is incorrect: all organic nitrates — including long-acting formulations at low doses — are absolutely contraindicated in HOCM because the mechanism of harm (venodilation with LV preload reduction and reduced LV volume) applies at any therapeutically effective nitrate concentration. There is no safe low-dose nitrate in HOCM.
• Option C: Option C is incorrect: there is no safe low dose of sublingual nitroglycerin in HOCM; the absolute contraindication applies to all doses and all nitrate formulations.
• Option D: Option D is incorrect: furosemide reduces preload through venous capacitance and diuresis, which decreases LV filling volume — worsening LVOT obstruction. Diuretics are not appropriate for angina management in HOCM unless there is concurrent volume overload from diastolic heart failure. CASE 6 D.L. is a 62-year-old man with stable coronary artery disease who presents to the emergency department with severe chest pain radiating to the left arm. His ECG shows diffuse ST depression. He is otherwise hemodynamically stable with a blood pressure of 148/88 mmHg. On direct questioning, he reports taking tadalafil (Cialis) 20 mg approximately 26 hours ago. ---

ANSWER: C

Rationale:

The correct answer is C. Tadalafil has a plasma half-life of approximately 17.5 hours — substantially longer than sildenafil (approximately 4 hours) and vardenafil (approximately 4–5 hours). Clinically significant plasma concentrations and PDE5 inhibitory activity persist for up to 48 hours after tadalafil ingestion. The absolute contraindication to all nitrate formulations is therefore set at 48 hours for tadalafil, compared with 24 hours for sildenafil and vardenafil. At 26 hours post-ingestion, D.L. remains within the 48-hour contraindication window. If nitroglycerin were administered, the combination of nitrate-generated cGMP and tadalafil-preserved cGMP would produce severe, potentially fatal hypotension. Nitroglycerin must be withheld entirely.

• Option A: Option A is incorrect: the 24-hour window applies to sildenafil and vardenafil, not to tadalafil; applying the shorter window to tadalafil is a potentially fatal clinical error that ignores tadalafil's prolonged pharmacokinetic profile.
• Option B: Option B is incorrect: the absolute contraindication applies to all nitrate formulations — sublingual, oral, transdermal, and intravenous. The short duration of sublingual NTG does not mitigate the pharmacodynamic cGMP potentiation that occurs at the vascular smooth muscle receptor level.
• Option D: Option D is incorrect: the 48-hour contraindication for tadalafil is not dose-dependent; it applies at all approved clinical doses (5 mg, 10 mg, 20 mg) because plasma concentrations at any therapeutic dose persist beyond 24 hours.
• Option E: Option E is incorrect: the contraindication is time-limited, not permanent; after 48 hours have elapsed since the last tadalafil dose, nitrates can be administered safely. ---

ANSWER: A

Rationale:

The correct answer is A. When nitrates are contraindicated due to recent PDE5 inhibitor use in a patient with NSTE-ACS, the standard approach is to manage ischemic symptoms with intravenous morphine — which provides analgesia and modest venodilation — supplemental oxygen (if hypoxic), and isotonic intravenous fluids to maintain preload and hemodynamic stability. Antiplatelet therapy (aspirin, P2Y12 inhibitor) and anticoagulation should also be initiated per ACS guidelines. Urgent cardiology evaluation for possible invasive coronary angiography and revascularization addresses the underlying cause of ischemia. The principle is that nitroglycerin is only one component of ACS management and its absence does not preclude effective urgent care.

• Option B: Option B is incorrect: all organic nitrates — regardless of their bioactivation pathway — are absolutely contraindicated with PDE5 inhibitors. Isosorbide dinitrate acts via the same NO-sGC-cGMP mechanism as nitroglycerin; it would produce the same dangerous cGMP potentiation with residual tadalafil.
• Option C: Option C is incorrect: amlodipine is a dihydropyridine calcium channel blocker with an onset of several hours — it is not an acute treatment for ischemic pain and does not provide the immediate coronary vasodilation of nitrates. CCBs are safe with PDE5 inhibitors but are not equivalent substitutes for acute nitrate therapy.
• Option D: Option D is incorrect: administering a second PDE5 inhibitor to potentiate the first is not a recognized or safe pharmacological strategy; this would dramatically amplify the risk of severe hypotension and is not appropriate management under any circumstances.
• Option E: Option E is incorrect: withholding all pharmacological therapy for ischemic symptoms in an NSTE-ACS presentation while waiting 48 hours is clinically unacceptable and dangerous — morphine, antiplatelet agents, anticoagulation, and urgent evaluation can and should proceed regardless of the nitrate contraindication. CASE 7 B.H. is a 69-year-old man admitted to the cardiac ICU following coronary artery bypass surgery. He has been receiving intravenous nitroglycerin at 9 mcg/kg/min for 42 hours for blood pressure management. The nursing staff notes that he has developed progressive cyanosis of the lips and fingertips over the past two hours. Supplemental oxygen at 10 L/min via non-rebreather mask has not improved his color. Pulse oximetry reads 84% on continuous monitoring despite an apparently adequate airway and ventilation confirmed on clinical examination. ---

ANSWER: D

Rationale:

The correct answer is D. Organic nitrates oxidize ferrous hemoglobin (Fe2+) to ferric methemoglobin (Fe3+). Methemoglobin cannot carry oxygen and causes a leftward shift of the oxyhemoglobin dissociation curve in remaining functional hemoglobin, impairing tissue oxygen delivery. The result is cyanosis that does not improve with supplemental oxygen — because the problem is not oxygen delivery to the alveoli but the inability of hemoglobin to transport oxygen to tissues. The characteristic pulse oximetry finding is a reading of approximately 84–85% regardless of actual oxygen saturation, because the standard two-wavelength oximeter cannot distinguish methemoglobin from oxyhemoglobin and defaults to this intermediate spurious value. Co-oximetry using multiple wavelengths is required for accurate diagnosis and will confirm elevated methemoglobin fraction. Methemoglobinemia is clinically significant at high-dose IV-NTG (greater than 5 mcg/kg/min for prolonged periods), which this patient has received at 9 mcg/kg/min for 42 hours.

• Option A: Option A is incorrect: tension pneumothorax causes hypoxemia through mechanical collapse and mediastinal shift with clinical findings of absent breath sounds, tracheal deviation, and hemodynamic compromise; it does not produce the characteristic 84–85% spurious pulse oximetry reading.
• Option B: Option B is incorrect: carboxyhemoglobin from carbon monoxide poisoning causes a falsely elevated (not 84–85%) pulse oximetry reading because standard two-wavelength oximetry reads carboxyhemoglobin as oxyhemoglobin, giving a near-normal spurious reading; the clinical context of prolonged high-dose IV-NTG distinguishes methemoglobinemia.
• Option C: Option C is incorrect: pulmonary embolism causes hypoxemia through ventilation-perfusion mismatch with preserved hemoglobin function; pulse oximetry would accurately reflect low oxygen saturation rather than producing the characteristic methemoglobin artifact.
• Option E: Option E is incorrect: IV-NTG is a potent preload reducer used to treat pulmonary edema, not cause it; furthermore, pulmonary edema would not explain the characteristic hemoglobin oxidation pattern. ---

ANSWER: B

Rationale:

The correct answer is B. Methylene blue is the definitive treatment for symptomatic methemoglobinemia. After intravenous administration, methylene blue is reduced by NADPH-dependent methemoglobin reductase (using NADPH generated by the hexose monophosphate shunt in erythrocytes) to leukomethylene blue, which then acts as an electron donor to reduce ferric methemoglobin (Fe3+) back to functional ferrous hemoglobin (Fe2+). The dose is 1–2 mg/kg IV, with clinical improvement typically within 30–60 minutes. The nitroglycerin infusion must also be discontinued to prevent ongoing methemoglobin generation. A methemoglobin fraction of 28% in a postoperative patient is clinically significant and requires immediate treatment.

• Option A: Option A is incorrect: hydroxocobalamin is the antidote for cyanide toxicity (a complication of sodium nitroprusside), not for methemoglobinemia; it works by binding cyanide, not by reducing ferric hemoglobin.
• Option C: Option C is incorrect: ascorbic acid (vitamin C) has some capacity to reduce methemoglobin but acts slowly and is considered a second-line or adjunctive treatment, not the definitive therapy; it is not appropriate as the primary treatment for a methemoglobin fraction of 28% in a symptomatic patient.
• Option D: Option D is incorrect: hyperbaric oxygen does increase dissolved plasma oxygen and may support tissue oxygenation, but it does not treat the underlying methemoglobinemia and is not the standard of care; methylene blue provides rapid and definitive reduction of methemoglobin and should not be bypassed in favor of hyperbaric therapy.
• Option E: Option E is incorrect: N-acetylcysteine replenishes glutathione and is used in acetaminophen toxicity and as an antioxidant adjunct in various conditions, but it is not the established treatment for methemoglobinemia; the NADPH-dependent methylene blue pathway is the pharmacologically correct mechanism for ferric hemoglobin reduction.